B+
Bull case
20%
Probability
Target price
$5.20
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
NKTX
NkartaDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
Current thesis
Nkarta has substantial reported runway, protocol changes that could broaden community access and enrollment, and a potentially value-creating 2026 NKX019 dataset. The stock's low absolute price leaves room for substantial upside if early clinical data are clearly positive.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +39.1.
What can break
Continued operating losses and eventual financing needs could create dilution despite the stated runway into 2029.
Momentum
70
Value
41
Sentiment
55
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.60 · Bull $5.20 · Bear $1.20Analysis 2026-08-08; returns require an exact persisted reference.
Data freshness
Prices
Unavailable: Price unavailable
Fundamentals
As of 2026-08-17 • Vendor: Data Vendor v1
Scores
As of 2026-09-09 • Model: HYBRID_IC_RP
AI Memo
As of 2026-08-08 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-09-09
Investment thesis
As of 2026-09-09
Grade is the composite factor band; factor scores use a 0–100 scale. Confidence describes evidence quality, not a probability of return. Score date: 2026-09-09. Definitions
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $10.83
Why
Momentum70 · Δ7d -3.8
Value41 · Δ7d 0.0
Sentiment55 · Δ7d +39.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Confirming evidence
- • Sentiment remains the lead driver in the composite, 7D delta +39.1.
Contradictions & invalidation
- • Continued operating losses and eventual financing needs could create dilution despite the stated runway into 2029.
- • NKX019 efficacy, durability, and safety remain unproven; early clinical data may disappoint or fail to support further development.
- • The company remains clinical-stage with no approved product, ongoing losses, and valuation concentrated in an unreported efficacy and safety readout.
Catalyst clock
2026-09-30
Cash runway remains near-term balance-sheet support
Lead driver: Sentiment · See AI snapshot
Momentum
70
9% active weight
Current posture
7d trendImproving
Δ7d
-3.8
Δ21d
-3.8
Value
41
28% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
+0.1
Sentiment
55
62% active weight
Current posture
7d trendImproving
Δ7d
+39.1
Δ21d
+39.1
Why this grade
Composite grade D. Momentum 70.2 / Value 41.2 / Sentiment 54.6
Scenario snapshot
Scenario probability is memo-authored likelihood, not forecast certainty. Targets belong to the analysis dated 2026-08-08. Scenario method
Most likely
B
Base case
50%
Probability
Target price
$2.60
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
B-
Bear case
30%
Probability
Target price
$1.20
Analysis reference price unavailable
Analysis 2026-08-08 · RankAlpha Sentiment Codex
Fundamentals (TTM)As of 2026-08-17
Fundamentals (TTM)
As of 2026-08-17
Market Cap
$174.05M
Beta
0.55
Shares Out
71.62M
P/E (TTM) · Derived
-1.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-1.92
Rev YoY
-100.0%
EPS YoY
+74.5%
Gross Margin
-
Op Margin
-
Net Debt
-$199.86M
Current Ratio
7.98
As of 2026-09-09 • Updated nightlySource: Internal modelMethods & Data